Men urged to cum at least 21 times a month to avoid #prostatecancer? Finally, an article from Sky News I can agree with! 😈

New targeted drug halts prostate cancer spread to bone in study

🧬 The new study reports that blocking the MDA-9/syntenin protein with the experimental drug IVMT-Rx-4 can stop prostate cancer cells spreading to bone in preclinical models. 🔗 www.sciencedirect.co... #HealthNews #CancerResearch #Oncology #ProstateCancer

Every year in the UK, more than 63,000 men are diagnosed with #PROSTATECANCER Far too many men find out at a later stage, when it's harder to treat! #TELLINME 🙄
PLEASE DONATE ON THE LINK BELOW AND SHARE THIS POST! #SHOULDADONE 😘
justgiving.com/.../here-she....

#MolecularImaging in Focus: Incorporating #PSMA PET into Risk Stratification for #ProstateCancer
www.diagnosticimaging.com/view/molecul...
#radiology #RadRes

Prostate Cancer Foundation and Hästens Launch Global Health Award to Expand Prostate Cancer Care in Emerging Countries — Inaugural Hästens-PCF Global Health Award will support expansion of STAMPEDE2 clinical trial in Nigeria — LOS ANGELES, Calif., March 31, 2026 – The Prostate Cancer Foundation (PCF) today announced t...

The Prostate Cancer Foundation announced the launch of the Hästens-PCF Global Health Award. 🏅

The award will support the expansion of STAMPEDE2 – a clinical trial testing new therapies in patients with advanced #ProstateCancer in Nigeria.

https://bit.ly/4cnQnXa

Horizontal bar graph showing risk of bias. Categories include: participation, attrition, prognostic factor measurement, outcome measurement, confounding, statistical analysis & reporting, and overall. Bias is rated as low, moderate, or high risk in percentage.

Pretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #ProstateCancer

ja.ma/4c30MGm

NBPF1 acts as a tumor suppressor in prostate cancer by regulating the PI3K/AKT pathway Introduction: Prostate cancer (PCa) is a leading malignancy in men, yet the roles of many candidate regulators remain unclear. Neuroblastoma breakpoint family member 1 (NBPF1) has been implicated as ...

#prostatecancer #cellproliferation #cellinvasion #PI3K/AKT #NBPF1

www.archivesofmedicalscience.com/NBPF1-acts-a...

Exploring the Causal Role of IgG N-Glycosylation in Urological Cancers: A Two-Sample Mendelian Randomization Study Using European Ancestry Datasets Introduction: Urological cancers pose a significant global health burden. Alterations in immunoglobulin G(IgG) N-glycosylation are implicated in cancer pathogenesis, but their causal role remains unc...

#MendelianRandomization #ImmunoglobulinG #BladderCancer #ProstateCancer #UrologicalNeoplasms #KidneyCancer #Glycosylation

www.archivesofmedicalscience.com/Exploring-th...

Combining PI-RADS v2.1 score with PSAD improves the diagnostic accuracy of transition zone prostate cancer Introduction: Transition zone (TZ) prostate cancer poses diagnostic challenges due to overlapping imaging features with benign prostatic hyperplasia (BPH). The study aims to investigate whether Prost...

#Prostatecancer #Transitionzone #antigendensity #ProstateImaging

www.archivesofmedicalscience.com/Combining-PI...

Meta-Analysis Shows Prognostic Impact of Prostate #MRI Prior to Radical Prostatectomy
www.diagnosticimaging.com/view/meta-an...
#radiology #RadRes #ProstateCancer

#ThrowbackThursday in JHC: "Satellite DNA Amplification in Advanced Prostate Cancer Is Largely Independent From Euchromatic and Oncogene Amplicons."

Click to read for FREE: bit.ly/3GmFOWW

#DNA #prostatecancer #chromosomemicroarray

🎙️ In a recent OncLive On Air podcast, David Morris, MD, FACS, and Alan Bryce, MD, discuss the FDA approval of rucaparib for patients with BRCA mutation–associated mCRPC.
🔗 Listen to the podcast: www.onclive.com/view/fda-app...
#ProstateCancer #mCRPC #PARPInhibitors #PrecisionOncology #Oncology

ASCO Publications

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced #ProstateCancer Treated With Enzalutamide. ascopubs.org/doi/10.1200/...

Conventional vs. Hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMR... Advances in radiation delivery techniques have markedly enhanced the precision of tumor targeting, allowing enhanced target dose escalation, while minimizing exposure to surrounding healthy tissues [1...

Conventional vs. Hypofractionated radiotherapy for high-risk #ProstateCancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT. www.thegreenjournal.com/article/S016...

[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 177Lu-PSMA-617 showed promising response rates and delayed disease progression in patients with oligometastatic HSPC in this trial. In addition, most treatment-related adverse events were low grade.

[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive #ProstateCancer (BULLSEYE): an open-label, randomised, phase 2 study. www.thelancet.com/journals/lan...

Antibody-drug conjugates are re-emerging as a promising strategy in advanced prostate cancer. This review examines key targets, clinical trial data, and how next-generation ADCs may overcome earlier limitations. Ther Adv Med Oncol
buff.ly/nFWU1s6
#ProstateCancer #ADCs #Oncology

#trends today for 'post quantum' 'quantum computers' & 'prostate cancer'

Click/Tap below:

www.newsmason.com?query=%22pos...

www.newsmason.com?query=%22qua...

www.newsmason.com?query=%22pro...

#postquantum #quantumcomputers #prostatecancer

🩺 Calling all prostate cancer survivors! Only 13 days left to join iCCaRE’s Prostate Cancer Advocacy Training.

📍 Jacksonville, FL | April 13, 2026
✅ Fully funded: travel, meals & certificate included
📝 Apply now: surveys.mayoclinic.org/jfe/form/SV_...

#ProstateCancer #CancerAdvocacy #iCCaRE

Could blocking key epigenetic androgen receptor co-regulators be a potential new treatment for advanced #ProstateCancer?

Prof. Nigel Mongan @uniofnottingham.bsky.social and team share promising novel findings in @moloncology.bsky.social.

Grab a ☕ and read: doi.org/10.1002/1878...

Please take a minute to share this post far and wide - it's not an exaggeration to say that you could be saving a life.
Thank you 🙏 to everyone who has supported our campaign so far.
#MensHealth #ProstateCancer #BuiltEnvironment #building #construction #collaboration
@prostatecanceruk.bsky.social

Prostate cancer in construction: do you know the risks? - Construction Management To mark Prostate Cancer Awareness Month, the latest episode of the 21CC podcast sets out why men across the industry must prioritise their health. Prostate cancer is the most common…

On the last day of #ProstateCancer Awareness Month I'm reiterating our call for as many people as possible to understand the symptoms and, for men, more about their risk.
This podcast covers these things, hopefully helping to normalise those conversations:
#MensHealth #BuiltEnvironment #construction

Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa? | Diagnostic Imaging In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive pros...

Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?
www.diagnosticimaging.com/view/pluvict...
#radiology #RadRes #ProstateCancer #NuclearMedicine

Abiraterone: Complete Guide for Prostate Cancer Patients in the Philippines Prostate cancer remains one of the most common cancers affecting men worldwide. The Philippines now offers advanced therapy Abiraterone, which has improved treatment results. The blog presents an e…

Abiraterone: Complete Guide for Prostate Cancer Patients in the Philippines

oddwaypharmaceuticalexporter.wordpress.com/2026/03/31/a...

#Abiraterone #AbirateroneAcetate #Healthcare #Blog #ProstateCancer #MedicineSupplierPhilippines #CancerTreatment

🆕Our April issue is live!

📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer

📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs

Cover: Spaceflight as a cancer research catalyst

www.thelancet.com/issue/S1470-...

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRnBZB !

#Oncology #SocialListening #LucidQuest

Denosumab-Adet Gains FDA Approval for All Indications of Denosumab | OncLive The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.
#oncology #FDA #medtwitter #prostatecancer #pcsm #bcsm
www.onclive.com/view/denosum...

How can one test support decisions across the #prostatecancer journey?

Hear how clinicians are using the #ArteraAI Prostate Test to guide care, from active surveillance to treatment decisions and recurrence.

Watch the replay: heyor.ca/w8m0LI

#PrecisionMedicine

Stop men dying needlessly from prostate cancer Can you spare a minute to help this campaign?

#ProstateCancer Please sign

c.org/YsgTS4tv2V

Updated Saskatoon Prostate Cancer Support Group Website:
www.pcssaskatoon.ca
#ProstateCancer #ProstateCancerSupport
#ProstateCancerAwareness
@prostatecanceruk.bsky.social @prostatepuncher.bsky.social @apccc.bsky.social @ubcmedicine.bsky.social @joycevance.bsky.social

William K. Oh Awarded EveryGrant by Conquer Cancer - Yale Cancer Center - OncoDaily William K. Oh Awarded EveryGrant by Conquer Cancer - Yale Cancer Center / cancer, OncoDaily, Oncology, prostate cancer, William K. Oh, Yale Cancer Center

Yale Cancer Center - William Oh Awarded EveryGrant by Conquer Cancer

@yalecancer.bsky.social @williamohmd.bsky.social

oncodaily.com/voices/yale-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ProstateCancer